Croatia, Pharma and Corruption - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Croatia, Pharma and Corruption
Croatia is on track to join the EU in 2013 and offers a well-developed pharmaceutical market. However, its EU membership application has undergone much scrutiny because of concerns regarding corruption, organised crime and counterfeit pharmaceuticals.


Pharmaceutical Technology Europe
Volume 23, Issue 8

References

1. BBC News, "Croatia cleared for EU membership in 2013" (UK, 2011). http://www.bbc.co.uk/, accessed 30 June 2011.

2. Business Monitor, Croatia Pharmaceuticals and Healthcare Report Q3 (UK, May 2011).

3. ANZAG, "ANZAG: Result under pressure" press release (Germany, 2011) http://www.anzag.de/, accessed 30 June 2011.

4. Epsicom, The Outlook for Pharmaceuticals in Central & Eastern Europe (UK, April 2011).

5. L. Voncina and T. Strizrep, Eurohealth 16 (4), 20–22 (2011).

6. L. Voncina "Croatian 2009–2010 pharma reform", Ekonom:east Media Group, online (Serbia, 2011), http://www.emg.rs/, accessed 30 June 2011.

7. FarmaVita.Net, "Croatia — Pharmaceuticals and Biotechnology" (2011), http://www.farmavita.net/, accessed 29 June 2011.

8. Pliva, "Pliva: History" (Croatia), http://www.pliva.com/, accessed 30 June 2011.

9. The Guardian, "US embassy cables: Allegations over Croatian pharmaceutical company deal rebutted" (UK, 2010) http://www.guardian.co.uk/, accessed 30 June 2011.

10. PETO EVIC, "Croatia Fights Counterfeiting" (Belgium, 2011). http://www.petosevic.com/, accessed 30 June 2011.

11. Securing Pharma, "Croatian study uncovers counterfeit medicines" (2010) http://www.securingpharma.com/, accessed 29 June 2011.

12. V. Stecher et al., 12th Congress of the European Society for Sexual Medicine (Lyon, France, 2009).


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
23%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
7%
All of the above.
47%
No government involvement in patient treatment or drug development.
9%
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
Source: Pharmaceutical Technology Europe,
Click here